Abstract:Background: Variability of PTX exposure using BSA dosing is well documented and often leads to severe toxicities. While carboplatin is dosed to obtain a specific exposure, paclitaxel is conventionally dosed by BSA, leading to a wide range of exposure. This study compared PTX PK-guided dosing to BSA dosing in a PTX-carboplatin regimen treating stage IIIB/IV NSCLC. This is the final analysis of interim results presented at ASCO 2015 (Poster #375). ClinicalTrials.gov Identifier NCT02058433. Methods: 309 patients with stage IIIB/IV NSCLC were randomized to receive up to 4 cycles of first line 3-weekly carboplatin (AUC 5) and a PTX dose of 175 mg/m2 (Arm A), or a PTX PK-guided dose (Arm B) to achieve a time above a PTX plasma concentration of 0.05µM (Tc>0.05) for 26 to 31 hours. Response was classified according to Response Evaluation Criteria in Solid Tumors Group. PTX concentrations were measured by immunoassay; Tc>0.05 was calculated with PK software. The primary endpoint was reduction of grade 4 hematological toxicities. Results: There were 164 patients in Arm A and 155 patients in Arm B, with 191 males and 128 females participating. PK-guided dose adjustment resulted in doses that were widely distributed 73 – 175 mg/m2, and statistically lower than in the BSA arm (by 24%, p < 0.001). Compared to Arm A, PK-guided dosing significantly reduced grade 4 neutropenia by 35% (p = 0.002, 23% vs. 16%) over 4 cycles. The incidence of severe (grade ≥3) neutropenia was also significantly reduced by 25% in Arm B over all cycles (p = <0.001). Additionally, neuropathy (≥ grade 2) was reduced from 20% in Arm A to 8% in Arm B (p = 0.008), representing a 60% reduction over all cycles. Response rates were not significantly different; objective response rates were 23% in Arm A and 29% in Arm B (p = 0.285); stable disease rates were 49% in Arm A and 42% in Arm B (p = 0.0.240). Conclusions: Results of this study are in agreement with a previous report, and present further evidence that PK-guided dosing reduces severe toxicities. This is accomplished by an overall lowering of dose intensity, while still maintaining efficacy. PK-guided dosing personalizes chemotherapy, and may be useful in patient management. Clinical trial identification: 02058433. Legal entity responsible for the study: Tonji University Affiliated Shanghai Pulmonary Hospital, Tongji University Funding: None Disclosure: All authors have declared no conflicts of interest. Keyword: PK-guided, neutropenia, neuropathy, paclitaxel

Role of TDM‐based dose adjustments for taxane anticancer drugs

Paclitaxel Therapeutic Drug Monitoring - International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations

Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer.

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

Taxanes in elderly breast cancer patients

Dermatological adverse events with taxane chemotherapy

Open-label Randomized Study of Individualized Pharmacokinetically (Pk)-Guided Dosing Versus Body Surface Area (BSA) Dosing of Paclitaxel (PTX) in Advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433

Mechanisms of Taxane Resistance

Pharmacologic differences in taxanes leading to difference in clinical activity and toxicity.

Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review

Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity

Taxane anticancer agents: a patent perspective

Weekly Paclitaxel/Docetaxel Combined with A Platinum in the Treatment of Advanced Non-Small Cell Lung Cancer: A Study on Efficacy, Safety and Pre-Medication

Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens

Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study

Genetic determinants of taxane-induced peripheral neuropathy

Assessing taxane-associated adverse events using the FDA adverse event reporting system database

Emerging nanotaxanes for cancer therapy

Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides

Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review